Isolated limb perfusion as a treatment option for rare types of tumours

References

• Creech O, Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616–32.
   PubMed Web of Science ®Google Scholar
• Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol 2013;39:311–19.
   PubMed Web of Science ®Google Scholar
• Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010;15:416–27.
   PubMed Web of Science ®Google Scholar
• Olofsson R, Mattsson J, Lindner P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int J Hyperthermia 2013;29:551–7.
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, van Geel AN, Verhoef C, Eggermont AM. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009;179:257–70.
   PubMedGoogle Scholar
• Olofsson R, Bergh P, Berlin O, Engstrom K, Gunterberg B, Hansson M, et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2012;19:1800–7.
   PubMed Web of Science ®Google Scholar
• Deroose JP, Grunhagen DJ, de Wilt JH, Eggermont AM, Verhoef C. Treatment modifications in tumour necrosis factor-alpha (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Eur J Cancer 2015;51:367–73.
   PubMed Web of Science ®Google Scholar
• Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999;134:303–7.
   PubMedGoogle Scholar
• Paramo JC, Benavides C, Tang LW, Martinez A, Cabello-Inchausti B, Davila E, et al. Complete remission of previously intractable peripheral cutaneous T-cell lymphoma of the lower extremity using isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard). Cancer Invest 2004;22:545–9.
   PubMed Web of Science ®Google Scholar
• Kobold S, Killic N, Lutkens T, Bokemeyer C, Fiedler W. Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type. Acta Haematol 2010;123:179–81.
   PubMed Web of Science ®Google Scholar
• Jansen RF, van Geel BN, van der Zee J, Hagenbeek A, Levendag PC. Intractible cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with 1-phenylalanine-mustard (melphalan, L-Pam). Cancer 1989;64:392–5.
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol 2005;31:912–16.
   PubMed Web of Science ®Google Scholar
• Zeitouni NC, Giordano CN, Kane JM III. In-transit Merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients. Dermatol Surg 2011;37:357–64.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
   Google Scholar
• Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998;40:807–14.
   PubMed Web of Science ®Google Scholar
• Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987;11:527–33.
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–10.
   PubMedGoogle Scholar
• Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 2014;3:46–53.
   PubMedGoogle Scholar
• Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013;347:f6153.
   PubMed Web of Science ®Google Scholar
• van Broekhoven DL, Deroose JP, Bonvalot S, Gronchi A, Grunhagen DJ, Eggermont AM, et al. Isolated limb perfusion using tumour necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. Br J Surg 2014;101:1674–80.
   PubMed Web of Science ®Google Scholar
• Di Grazia S, Succi G, Fragetta F, Perrotta RE. Giant cell tumor of tendon sheath: study of 64 cases and review of literature. G Chir 2013;34:149–52.
   PubMedGoogle Scholar
• Vermeer MH, Willemze R. Recent advances in primary cutaneous B-cell lymphomas. Curr Opin Oncol 2014;26:230–6.
   PubMed Web of Science ®Google Scholar
• Elhassadi E, Egan E, O'Sullivan G, Mohamed R. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 2006;28:279–81.
   PubMedGoogle Scholar
• Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001;27:390–5.
   PubMed Web of Science ®Google Scholar